Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have received an average recommendation of “Buy” from the twenty-one ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $206.82.

SRPT has been the topic of a number of research analyst reports. HC Wainwright set a $267.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 17th. Morgan Stanley dropped their target price on shares of Virtus Investment Partners from $121.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Tuesday, July 9th. Cowen restated a “buy” rating and issued a $77.00 target price on shares of Centene in a research note on Sunday, March 31st. Royal Bank of Canada downgraded shares of Roku from an “outperform” rating to a “sector perform” rating and set a $90.00 target price on the stock. in a research note on Monday, July 1st. They noted that the move was a valuation call. Finally, Piper Jaffray Companies restated a “hold” rating on shares of Seattle Genetics in a research note on Thursday, March 28th.

In other news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the transaction, the director now directly owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its holdings in Sarepta Therapeutics by 383,486.0% in the second quarter. Bessemer Group Inc. now owns 218,644 shares of the biotechnology company’s stock valued at $33,223,000 after buying an additional 218,587 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in Sarepta Therapeutics by 3.2% in the second quarter. Commonwealth Equity Services LLC now owns 9,454 shares of the biotechnology company’s stock valued at $1,436,000 after buying an additional 290 shares in the last quarter. Wealthstreet Investment Advisors LLC increased its holdings in Sarepta Therapeutics by 18.4% in the second quarter. Wealthstreet Investment Advisors LLC now owns 7,720 shares of the biotechnology company’s stock valued at $1,173,000 after buying an additional 1,200 shares in the last quarter. Fagan Associates Inc. purchased a new position in Sarepta Therapeutics in the second quarter valued at $938,000. Finally, E&G Advisors LP purchased a new position in Sarepta Therapeutics in the second quarter valued at $209,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Sarepta Therapeutics stock traded down $2.37 during midday trading on Friday, reaching $149.26. The stock had a trading volume of 946,860 shares, compared to its average volume of 1,237,047. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. Sarepta Therapeutics has a 52-week low of $95.21 and a 52-week high of $165.87. The company has a market capitalization of $11.06 billion, a price-to-earnings ratio of -27.34 and a beta of 2.12. The stock has a fifty day simple moving average of $136.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.05) by $0.98. The company had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. On average, equities analysts forecast that Sarepta Therapeutics will post -4.04 EPS for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Recommended Story: How Do You Make Money With Penny Stocks?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.